Adverse events in pregnant women with the tetravalent influenza vaccine obtained from cell cultures

  1. Carreras, Juan José
  2. Lluch, José Antonio
  3. Taboada, José Antonio
  4. Pastor-Villalba, Eliseo
  5. Nartallo-Penas, Victoria
  6. Díez-Domingo, Javier
Revista:
Enfermedades infecciosas y microbiologia clinica (English ed.)

ISSN: 2529-993X

Ano de publicación: 2023

Volume: 41

Número: 7

Páxinas: 420-422

Tipo: Artigo

DOI: 10.1016/J.EIMCE.2022.11.005 GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Enfermedades infecciosas y microbiologia clinica (English ed.)

Obxectivos de Desenvolvemento Sustentable

Resumo

Influenza vaccination in pregnant women shows a clear benefit/risk ratio. Influenza vaccines are currently being developed using new platforms. It is essential to analyse the safety of these new vaccines in this population group, underrepresented in clinical trials. In the 2019-2020 season, a vaccine obtained in cell culture was recommended to pregnant women in two autonomous communities. Information is collected from the vaccination and pharmacovigilance centres of both communities. The reporting rate of adverse events (AEs) after vaccination in pregnant women was 4.02/100,000 doses administered, and in non-pregnant women aged 18-64 years it was 5.9/100,000 doses administered. The rate of AE reported was 8.04 and 17.74 respectively. No spontaneous abortions, prematurity or foetal malformations were reported. This analysis suggests the safety in pregnant women of the influenza vaccine obtained from cell cultures.

Referencias bibliográficas

  • Limia Sánchez A, Navarro JA, Armona Aquerreta JM. Mujeres en edad fértil, embarazadas y puerperio. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. 2018 July. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/riesgo/docs/Mujeres_embarazadas_puerperio.pdf. [Accessed 28 January 2022].
  • Szymczakiewicz-Multanowska, (2012), Hum Vaccines Immunother, 8, pp. 645, 10.4161/hv.19493
  • Agencia Española de Medicamentos y Productos Sanitarios. Ficha tecnica Flucelvax tetra suspension inyectable en jeringa precargada. [Accessed 28 January 2022]. Available from: https://cima.aemps.es/cima/dochtml/ft/1181325001/FT_1181325001.html.
  • Rothman, (2004), Pharmacoepidemiol Drug Saf, 13, pp. 519, 10.1002/pds.1001
  • Pérez-Vilar, (2015), Hum Vaccines Immunother, 11, pp. 1848, 10.1080/21645515.2015.1049787
  • Moro, (2021), Vaccine, 39, pp. 678, 10.1016/j.vaccine.2020.12.045
  • Varallo, (2014), Rev da Esc Enferm, 48, pp. 739, 10.1590/S0080-623420140000400023
  • Consejo Interterritorial del Sistema Nacional de Salud
  • Bratton, (2015), Clin Infect Dis, 60, pp. e11, 10.1093/cid/ciu915